← Back to Search

Exercise Training for High Blood Pressure

N/A
Waitlist Available
Led By Marc Cook, PhD
Research Sponsored by North Carolina Agriculture & Technical State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
30-50 years of age
Elevated to Stage 1 Hypertension (systolic BP: 120-129 mmHg/diastolic BP: 80-89 mmHg) and/or stage 1 hypertension (systolic BP: 130-159 mmHg/diastolic BP: 90-99 mmHg)
Must not have
Diagnosed with peripheral vascular disease
Diagnosed with liver disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether exercise can help lower blood pressure by improving gut microbial health in African Americans.

Who is the study for?
This trial is for African Americans aged 30-50 who are sedentary, have slightly elevated to stage 1 high blood pressure but no other major health issues like heart disease, kidney or lung diseases, and aren't on medications that affect blood pressure. Smokers and pregnant women can't participate.
What is being tested?
The study investigates how exercise training affects high blood pressure and gut microbial diversity in African Americans. It aims to understand if improving gut health through exercise can help lower blood pressure.
What are the potential side effects?
Since the intervention involves exercise training, potential side effects may include muscle soreness, fatigue, or injury related to physical activity. However, these are generally mild and manageable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 30 and 50 years old.
Select...
My blood pressure is in the range of 120-159/80-99 mmHg.
Select...
I am between 30 and 50 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with peripheral vascular disease.
Select...
I have been diagnosed with liver disease.
Select...
I have been diagnosed with kidney stones or gallbladder issues.
Select...
I have uncontrolled high blood pressure or a history of heart issues.
Select...
I have been diagnosed with kidney disease.
Select...
I have been diagnosed with an inflammatory disease like IBD, rheumatoid arthritis, or lupus.
Select...
I have been diagnosed with diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood Pressure
Gut Dysbiosis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Hypertension (Exercise Intervention)Experimental Treatment1 Intervention
Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.

Find a Location

Who is running the clinical trial?

North Carolina Agriculture & Technical State UniversityLead Sponsor
8 Previous Clinical Trials
140 Total Patients Enrolled
Marc Cook, PhDPrincipal InvestigatorNorth Carolina Agriculture & Technical State University

Media Library

Exercise Training Clinical Trial Eligibility Overview. Trial Name: NCT03897777 — N/A
High Blood Pressure Research Study Groups: Hypertension (Exercise Intervention)
High Blood Pressure Clinical Trial 2023: Exercise Training Highlights & Side Effects. Trial Name: NCT03897777 — N/A
Exercise Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT03897777 — N/A
~7 spots leftby Jun 2026